{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:19:19Z","timestamp":1789510759194,"version":"build-2803163510"},"reference-count":149,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Clinical and mechanistic considerations in idiosyncratic drug-induced liver injury (iDILI) remain challenging topics when they are derived from mere case narratives or iDILI cases without valid diagnosis. To overcome these issues, attempts should be made on pathogenetic aspects based on published clinical iDILI cases firmly diagnosed by the original RUCAM (Roussel Uclaf Causality Assessment Method) or the RUCAM version updated in 2016. Analysis of RUCAM-based iDILI cases allowed for evaluating immune and genetic data obtained from the serum and the liver of affected patients. For instance, strong evidence for immune reactions in the liver of patients with RUCAM-based iDILI was provided by the detection of serum anti-CYP 2E1 due to drugs like volatile anesthetics sevoflurane and desflurane, partially associated with the formation of trifluoroacetyl (TFA) halide as toxic intermediates that form protein adducts and may generate reactive oxygen species (ROS). This is accompanied by production of anti-TFA antibodies detected in the serum of these patients. Other RUCAM-based studies on serum ANA (anti-nuclear antibodies) and SMA (anti-smooth muscle antibodies) associated with AIDILI (autoimmune DILI) syn DIAIH (drug-induced autoimmune hepatitis) provide additional evidence of immunological reactions with monocytes as one of several promoting immune cells. In addition, in the blood plasma of patients, mediators like the cytokines IL-22, IL-22 binding protein (IL-22BP), IL-6, IL-10, IL 12p70, IL-17A, IL-23, IP-10, or chemokines such as CD206 and sCD163 were found in DILI due to anti-tuberculosis drugs as ascertained by the prospective updated RUCAM, which scored a high causality. RUCAM-based analysis also provided compelling evidence of genetic factors such as HLA (human leucocyte antigen) alleles contributing to initiate iDILI by a few drugs. In conclusion, analysis of published RUCAM-based iDILI cases provided firm evidence of immune and genetic processes involved in iDILI caused by specific drugs.<\/jats:p>","DOI":"10.3390\/ijms241310855","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:43:30Z","timestamp":1688085810000},"page":"10855","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-1200","authenticated-orcid":false,"given":"Rolf","family":"Teschke","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt\/Main, Leimenstrasse 20, D-63450 Hanau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7580-1505","authenticated-orcid":false,"given":"Gaby","family":"Danan","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Consultancy, Rue des Ormeaux, 75020 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17562848231163410","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: A comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_2","first-page":"1","article-title":"Selected highlights and controversies of drug-induced liver injury from the recent literature","volume":"1","author":"Rosenberg","year":"2020","journal-title":"World J. Gastroenterol. Hepatol. Endosc. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40264-021-01109-4","article-title":"Drug-induced liver injury: Highlights and controversies in the recent literature","volume":"44","author":"Clinton","year":"2021","journal-title":"Drug Saf."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Teschke, R., and Danan, G. (2020). Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993\u2013mid 2020: A comprehensive analysis. Medicines, 7.","DOI":"10.3390\/medicines7100062"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2014I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Danan, G., and Teschke, R. (2016). RUCAM in drug and herb induced liver injury: The update. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010014"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1665-2681(19)30888-9","article-title":"Drug induced liver injury: Accuracy of diagnosis in published reports","volume":"13","author":"Teschke","year":"2014","journal-title":"Ann. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/bcp.13593","article-title":"Review: Drug induced liver injury with analysis of alternative causes as confounding variables","volume":"84","author":"Teschke","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Teschke, R., and Danan, G. (2021). Idiosyncratic drug-induced liver injury (DILI) and herb-induced liver injury (HILI): Diagnostic algorithm based on the quantitative Roussel Uclaf Causality Assessment Method (RUCAM). Diagnostics, 11.","DOI":"10.3390\/diagnostics11030458"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e010621192456","DOI":"10.2174\/2666290601666210325091553","article-title":"DILI cases in registries and databases: An analysis of quality","volume":"1","author":"Teschke","year":"2022","journal-title":"Int. J. Gastroenterol. Hepatol. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3389\/fphar.2020.00842","article-title":"Knowledge mapping of drug-induced liver injury: A scientometric investigation (2010\u20132019)","volume":"11","author":"Ke","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Teschke, R., and Danan, G. (2021). The LiverTox paradox-gaps between promised data and reality check. Diagnostics, 11.","DOI":"10.3390\/diagnostics11101754"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2050313X20917822","DOI":"10.1177\/2050313X20917822","article-title":"A possible increase in liver enzymes due to amlodipine: A case report","volume":"8","author":"Varghese","year":"2020","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2040622320964152","DOI":"10.1177\/2040622320964152","article-title":"Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes","volume":"11","year":"2020","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"ref_15","first-page":"e7299","article-title":"Autoimmune-like drug-induced liver injury caused by atorvastatin and demonstration of the safety profile of pravastatin: A case report and literature review","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10620-020-06730-4","article-title":"If DILI is suspected, don\u2019t dally","volume":"66","author":"Abbass","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_17","first-page":"959","article-title":"Candesartan-induced cholestatic hepatitis: A case report","volume":"112","year":"2020","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_18","first-page":"001612","article-title":"A fatal case of ciprofloxacin-induced fulminant hepatitis","volume":"7","author":"Napier","year":"2020","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jcpt.13042","article-title":"Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database","volume":"45","author":"Ma","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1590\/1806-9282.66.1.12","article-title":"Flucloxacillin-induced hepatotoxicity: Association with HLA-B*5701","volume":"66","author":"Teixeira","year":"2020","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_21","first-page":"8812983","article-title":"A severe case of drug-induced liver injury after gemcitabine administration: A highly probable causality grading as assessed by the updated RUCAM diagnostic scoring system","volume":"2020","author":"Mascherona","year":"2020","journal-title":"Case Rep. Hepatol."},{"key":"ref_22","first-page":"162","article-title":"Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: The IDLE study","volume":"33","author":"Worland","year":"2020","journal-title":"Ann. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/bcp.14254","article-title":"Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury","volume":"86","author":"Sebode","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/24734306.2020.1835413","article-title":"A case of teriflunomide-induced hepatic injury: Assessing causality using available rules","volume":"4","author":"LeSaint","year":"2020","journal-title":"Toxicol. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.aohep.2018.11.008","article-title":"Epidemiology of drug-induced liver injury in a University Hospital from Colombia: Updated RUCAM being used for prospective causality assessment","volume":"18","author":"Amariles","year":"2019","journal-title":"Ann. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chen, X., Hao, Z., Pan, H., Liu, W., Lu, L., Zhang, M., He, X., Yi, H., and Tang, S. (2023). Relationship between common telomere length-related genetic variations, telomere length, and risk of antituberculosis drug-induced hepatotoxicity in Chinese Han population: As assessed for causality using the updated Roussel Uclaf Causality Assessment Method. Fundam. Clin. Pharmacol., 2\u201328.","DOI":"10.1111\/fcp.12885"},{"key":"ref_27","first-page":"8894498","article-title":"Epidemiology of drug- and herb-induced liver injury assessed for causality using the updated RUCAM in two hospitals from China","volume":"2021","author":"Chen","year":"2021","journal-title":"BioMed Res. Int."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Danjuma, M.I.M., Almasri, H., Alshokri, S., Khir, F.K., Elmalik, A., Battikh, N.G., Abdallah, I.M.H.A., Elshafei, M., Fatima, H., and Mohamed, M.F.H. (2020). Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score. BMC Geriatr., 20.","DOI":"10.1186\/s12877-020-01732-3"},{"key":"ref_29","first-page":"3105","article-title":"A case report of a drug-induced liver injury (DILI) caused by multiple antidepressants with causality established by the updated Roussel Uclaf causality assessment method (RUCAM) and in vitro testing","volume":"8","author":"Stewart","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.30968\/rbfhss.2022.132.0791","article-title":"Drug-induced liver injury causality assessment data from a crosssectional study In Brazil: A call for the use of updated RUCAM in hospital pharmacy","volume":"13","author":"Lunardelli","year":"2022","journal-title":"Rev. Bras. Farm. Hosp. Serv. Saude."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"819589","DOI":"10.3389\/fphar.2022.819589","article-title":"Utility of lymphoycyte transformation test for assisting updated Roussel Uclaf Causality Assessment Method in drug-induced liver injury: A case-control study","volume":"13","author":"Soto","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1002126","DOI":"10.3389\/fimmu.2022.1002126","article-title":"Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM: A prospective study","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"790108","DOI":"10.3389\/fphar.2021.790108","article-title":"Causality evaluation of drug-induced liver injury in newborns and children in the intensive care unit using the updated Roussel Uclaf Causality Assessment Method","volume":"12","author":"Ye","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e000549","DOI":"10.1136\/bmjgast-2020-000549","article-title":"Androgenic anabolic steroid-induced liver injury: Two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature","volume":"7","author":"Abeles","year":"2020","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_35","first-page":"5090200","article-title":"Acute liver failure following a single dose of Atezolizumab, as assessed for causality using the updated RUCAM","volume":"2022","author":"Tzadok","year":"2022","journal-title":"Case Rep. Gastrointest. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3389\/fphar.2019.00816","article-title":"Comparison of different liver test thresholds for drug-induced liver injury: Updated RUCAM versus other methods","volume":"10","author":"Yang","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5914593","DOI":"10.1155\/2022\/5914593","article-title":"Drug-induced liver injury during consolidation therapy in childhood acute lymphoblastic leukemia as assessed for causality using the updated RUCAM","volume":"2022","author":"Qin","year":"2022","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Giacomelli, A., Riva, A., Falvella, F.S., Oreni, M.L., Cattaneo, D., Cheli, S., Renisi, G., Di Cristo, V., Lupo, A., and Clementi, E. (2018). Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3462-5"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"966910","DOI":"10.3389\/fphar.2022.966910","article-title":"Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM","volume":"13","author":"Tampe","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e250422203997","DOI":"10.2174\/2666290601666220425104715","article-title":"Severe DILI in a patient under polypharmacy including rosuvastatin: Diagnostic challenges and lessons from a case report assessed using the updated RUCAM algorithm","volume":"1","author":"Teschke","year":"2022","journal-title":"Int. J. Gastroenterol. Hepatol. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Studentova, H., Volakova, J., Spisarova, M., Zemankova, A., Aiglova, K., Szotkowski, T., and Melichar, B. (2022). Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: Two case reports assessed for causality using the updated RUCAM and review of the literature. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02121-3"},{"key":"ref_42","first-page":"6331923","article-title":"A case of delayed hepatic injury associated with teriflunomide use as assessed for causality using the updated RUCAM","volume":"2022","author":"Wurzburger","year":"2022","journal-title":"Case Rep. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Shi, X., Lao, D., Xu, Q., Li, X., and Lv, Q. (2022). A case report of drug-induced liver injury after tigecycline administration: Histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07258-w"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Olsson","year":"2005","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Vigan\u00f2, M., La Milia, M., Grassini, M.V., Pugliese, N., De Giorgio, M., and Fagiuoli, S. (2023). Hepatotoxicity of small molecule protein kinase inhibitors for cancer. Cancers, 15.","DOI":"10.3390\/cancers15061766"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Teschke, R. (2023). Treatment of drug-induced liver injury. In Special Issue: Liver Disease and Therapy, Guest Editor: Nahum M\u00e9ndez-S\u00e1nchez. Biomedicines, 11.","DOI":"10.3390\/biomedicines11010015"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1111\/liv.14516","article-title":"First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19","volume":"40","year":"2020","journal-title":"Liver Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100267","DOI":"10.1016\/j.aohep.2020.09.011","article-title":"Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases","volume":"21","author":"Chen","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Delgado, A., Stewart, S., Urroz, M., Rodr\u00edguez, A., Borobia, A.M., Akatbach-Bousaid, I., Gonz\u00e1lez-Mu\u00f1oz, M., and Ram\u00edrez, E. (2021). Characterisation of drug-induced liver injury in patients with COVID-19 detected by a Proactive Pharmacovigilance Program from laboratory signals. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194432"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jceh.2021.02.006","article-title":"Severe jaundice in a COVID-19 patient-virus or drug?","volume":"11","author":"Jothimani","year":"2021","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_53","first-page":"276","article-title":"Letter to the Editor. Favipiravir-induced liver injury in patients with coronavirus disease 2019","volume":"9","author":"Kumar","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jiac.2020.12.021","article-title":"Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19","volume":"27","author":"Yamazaki","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/MEG.0000000000002381","article-title":"Clinical features and predictive factors related to liver injury in SARS-CoV-2 Delta and Omicron variant-infected patients","volume":"34","author":"Deng","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Naseralallah, L.M., Aboujabal, B.A., Geryo, N.M., Al Boinin, A., Al Hattab, F., Akbar, R., Umer, W., Abdul Jabbar, L., and Danjuma, M.I. (2022). The determination of causality of drug induced liver injury in patients with COVID-19 clinical syndrome. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0268705"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Teschke, R., M\u00e9ndez-S\u00e1nchez, N., and Eickhoff, A. (2022). Liver injury in COVID-19 patients with drugs as causatives: A systematic review of 996 DILI cases published 2020\/2021 based on RUCAM as causality assessment method. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094828"},{"key":"ref_58","unstructured":"Preedy, V.R. (2023). Thematic Approaches to COVID-19, Elsevier. in press."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jhep.2020.04.006","article-title":"COVID-19: Abnormal liver function tests","volume":"73","author":"Cai","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4254\/wjh.v12.i8.413","article-title":"Mechanisms and consequences of COVID-19 associated liver injury: What can we affirm?","volume":"12","author":"Brito","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.biochi.2020.08.018","article-title":"Treatments in COVID-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?","volume":"179","author":"Ferron","year":"2020","journal-title":"Biochimie"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3389\/fphar.2019.00853","article-title":"Roussel Uclaf Causality Assessment Method for drug-induced liver injury: Present and future","volume":"10","author":"Danan","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1053\/j.gastro.2015.04.027","article-title":"Editorial. Drug-induced liver injury: Expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment","volume":"148","author":"Teschke","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chen, M., and Will, Y. (2018). Drug-Induced Liver Toxicity (Chapter 27), Springer Nature. (Series: Methods in Pharmacology and Toxicology\/Y. James Kang & David C. Casey).","DOI":"10.1007\/978-1-4939-7677-5"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1002\/hep.32440","article-title":"Letter to the editor. Electronic RUCAM: Major pitfalls call for caution and proper validation","volume":"76","author":"Danan","year":"2022","journal-title":"Hepatology"},{"key":"ref_66","first-page":"116","article-title":"Presentation of drug-induced liver injury in Singapore","volume":"47","author":"Wai","year":"2006","journal-title":"Singap. Med. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/hep.21424","article-title":"Outcome of acute idiosyncratic drug-induced liver injury: Long term follow-up in a hepatotoxicity registry","volume":"44","author":"Andrade","year":"2006","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2036.2008.03655.x","article-title":"Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury","volume":"27","author":"Lucena","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/ajg.2010.287","article-title":"Single center experience with drug-induced liver injury from India: Causes, outcome, prognosis, and predictors of mortality","volume":"105","author":"Devarbhavi","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Spanish Dili Registry, Eudragene, Dilin, Diligen, and International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Jacobsen","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Stephens, C., L\u00f3pez-Nevot, M.-\u00c1., Ruiz-Cabello, F., Ulzurrun, E., Soriano, G., Romero-G\u00f3mez, M., Moreno-Casares, A., Lucena, M.I., and Andrade, R.J. (2013). HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS ONE, 8, Erratum in PLoS ONE 2014, 9, e112165.","DOI":"10.1371\/journal.pone.0112165"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bergmann","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/bcp.12565","article-title":"Drug-induced liver injury: Results from the hospital-based Berlin case-control surveillance study","volume":"79","author":"Douros","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/apt.13023","article-title":"Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids","volume":"41","author":"Stephens","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/jgh.13323","article-title":"Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients","volume":"31","author":"Zhu","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"442","DOI":"10.5604\/01.3001.0009.8600","article-title":"Drug induced liver injury at a tertiary hospital in India: Etiology, clinical features and predictors of mortality","volume":"16","author":"Rathi","year":"2017","journal-title":"Ann. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rnsson, E.S. (2016). Hepatotoxicity by drugs: The most common implicated agents. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17020224"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports","volume":"63","author":"Hoofnagle","year":"2016","journal-title":"Hepatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/bmj.319.7224.1541","article-title":"Accuracy of hepatic adverse drug reaction reporting in one English health region","volume":"319","author":"Aithal","year":"1999","journal-title":"Br. Med. J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gut.44.5.731","article-title":"The natural history of histologically proved drug induced liver disease","volume":"44","author":"Aithal","year":"1999","journal-title":"Gut"},{"key":"ref_82","unstructured":"Seto, W.-K., and Eslam, M. (2023). Comprehensive Guide to Hepatitis Advances, Academic Press."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40264-018-0654-2","article-title":"Drug-induced liver injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch?","volume":"41","author":"Danan","year":"2018","journal-title":"Drug Saf."},{"key":"ref_84","first-page":"4","article-title":"DILI, HILI, RUCAM algorithm, and AI, the Artificial Intelligence: Provocative issues, progress, and proposals","volume":"1","author":"Teschke","year":"2020","journal-title":"Arch. Gastroenterol. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions of drugs\u2013II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge","volume":"46","author":"Danan","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Iorga, A., Dara, L., and Kaplowitz, N. (2017). Drug-Induced Liver Injury: Cascade of events leading to cell death, apoptosis or necrosis. In Special Issue: Molecular Research on Drug Induced liver Injury, academic editors: Rolf Teschke, Gaby Danan. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18051018"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Villanueva-Paz, M., Mor\u00e1n, L., L\u00f3pez-Alc\u00e1ntara, N., Freixo, C., Andrade, R.J., Lucena, M.I., and Cubero, F.J. (2021). Oxidative stress in drug-induced liver injury (DILI): From mechanisms to biomarkers for use in clinical practice. Antioxidants, 10.","DOI":"10.3390\/antiox10030390"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3748\/wjg.v24.i13.1373","article-title":"Dissecting the molecular pathophysiology of drug-induced liver injury","volume":"24","author":"Ye","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3389\/fphar.2019.00837","article-title":"Mechanistic studies of idiosyncratic DILI: Clinical implications","volume":"10","author":"Uetrecht","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13062-020-00285-0","article-title":"Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure","volume":"16","author":"Liu","year":"2021","journal-title":"Biol. Direct."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Mihajlovic, M., and Vinken, M. (2022). Mitochondria as the target of hepatotoxicity and drug-induced liver injury: Molecular mechanisms and detection methods. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063315"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4168\/aair.2016.8.1.3","article-title":"Update on advances in research on idiosyncratic drug-induced liver injury","volume":"8","author":"Kim","year":"2016","journal-title":"Allergy. Asthma. Immunol. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2","DOI":"10.12701\/yujm.2019.00297","article-title":"Drug-induced liver injury","volume":"37","author":"Suh","year":"2020","journal-title":"Yeungnam Univ. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfab069","article-title":"Analytical and Omics-based advances in the study of drug-induced liver injury","volume":"183","author":"Kralj","year":"2021","journal-title":"Toxicol. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1124\/jpet.121.000828","article-title":"Novel bile acid-dependent mechanisms of hepatotoxicity associated with tyrosine kinase inhibitors","volume":"380","author":"Saran","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4254\/wjh.v9.i10.491","article-title":"Drug-induced liver injury: Do we know everything?","volume":"9","author":"Alempijevic","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Lee, S.K., Choi, J.Y., Jung, E.S., Kwon, J.H., Jang, J.W., Bae, S.H., and Yoon, S.K. (2023). An immunological perspective on the mechanism of drug induced liver injury: Focused on drugs for treatment of hepatocellular carcinoma and liver transplantation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24055002"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1016\/j.apsb.2021.11.013","article-title":"Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction","volume":"11","author":"Andrade","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9176937","DOI":"10.1155\/2017\/9176937","article-title":"Idiosyncratic drug-induced liver injury (IDILI): Potential mechanisms and predictive assays","volume":"2017","author":"Roth","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1077468","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3389\/fphar.2019.01482","article-title":"Drug-induced liver injury: Biomarkers, requirements, candidates, and validation","volume":"10","author":"Meunier","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"730","DOI":"10.21037\/atm-2020-ubih-05","article-title":"Mechanism of idiosyncratic drug induced liver injury (DILI): Unresolved basic issues. In special issue: Unresolved basic issues in hepatology, guest editors Ralf Weiskirchen, Wolfgang Stremmel","volume":"9","author":"Teschke","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., and Ivernizzi, P. (2021). Immune-mediated drug-induced liver injury: Immunogenetics and experimental models. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094557"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Teschke, R. (2023). Molecular idiosyncratic toxicology of drugs in the human liver compared with animals: Basic considerations. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076663"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"bcr2012006543","DOI":"10.1136\/bcr-2012-006543","article-title":"Repeated exposure to modern volatile aesthetics may cause chronic hepatitis as well as acute liver injury","volume":"2012","author":"Nicoll","year":"2012","journal-title":"BMJ Case Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/apt.15168","article-title":"A prospective study of the incidence of drug-induced liver injury by the modern volatile anaesthetics sevoflurane and desflurane","volume":"49","author":"Bishop","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.redox.2014.11.004","article-title":"CYP2E1 autoantibodies in liver diseases","volume":"3","author":"Sutti","year":"2014","journal-title":"Redox. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Teschke, R., and Danan, G. (2021). Idiosyncratic drug induced liver injury, cytochrome P450, metabolic risk factors and lipophilicity: Highlights and controversies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073441"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Jee, A., Sernoskie, S.C., and Uetrecht, J. (2021). Idiosyncratic drug-induced liver injury: Mechanistic and clinical challenges. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062954"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1128\/CVI.13.2.258-265.2006","article-title":"Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in the pathogenesis of idiosyncratic drug-induced hepatitis","volume":"13","author":"Njoku","year":"2006","journal-title":"Clin. Vaccine. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1021\/tx960083q","article-title":"Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis","volume":"9","author":"Bourdi","year":"1996","journal-title":"Chem. Res. Toxicol."},{"key":"ref_113","first-page":"733","article-title":"Identification by immunoblotting of 3 halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis","volume":"242","author":"Kenna","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1213\/00000539-200202000-00003","article-title":"Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists","volume":"94","author":"Njoku","year":"2002","journal-title":"Anesth. Analgesia."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/tx700186p","article-title":"Idiosyncratic drug reactions: Past, present, and future","volume":"21","author":"Uetrecht","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-2002-30105","article-title":"Epidemiology and individual susceptibility to adverse drug reactions affecting the liver","volume":"22","author":"Larrey","year":"2002","journal-title":"Semin. Liver Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1111\/liv.14985","article-title":"Drug-induced liver injury at a tertiary care centre in Germany: Model for end-stage liver disease is the best predictor of outcome","volume":"41","author":"Zenouzi","year":"2021","journal-title":"Liver Int."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.3748\/wjg.v22.i33.7579","article-title":"Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis","volume":"22","author":"Yang","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gutjnl-2015-309528","article-title":"Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury","volume":"65","author":"Benesic","year":"2016","journal-title":"Gut"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fphar.2018.00699","article-title":"Proteomics analysis of monocyte-derived hepatocyte-like cells identifies Integrin Beta 3 as a specific biomarker for drug-induced liver injury by Diclofenac","volume":"9","author":"Dragoi","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/hep.28270","article-title":"Drug-induced liver injury associated with Stevens-Johnson syndrome\/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases","volume":"63","author":"Devarbhavi","year":"2016","journal-title":"Hepatology"},{"key":"ref_122","unstructured":"Espinoza, V.E., and Emmady, P.D. (2022). StatPearls (Internet), StatPearls Publishing."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Ho, C.M., Chen, C.L., Chang, C.H., Lee, M.R., Wang, J.Y., Hu, R.H., and Lee, P.H. (2021). Circulatory inflammatory mediators in the prediction of anti-tuberculous drug-induced liver injury using RUCAM for causality assessment. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080891"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3748\/wjg.v28.i24.2654","article-title":"Drug-induced autoimmune hepatitis: A minireview","volume":"28","author":"Tan","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.dld.2014.08.040","article-title":"Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study","volume":"46","author":"Licata","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2021.01.029","article-title":"Participating clinical centres. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry","volume":"75","author":"Stephens","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2016.05.043","article-title":"Drug-Induced Liver Injury Network. Features of autoimmune hepatitis in patients with drug-induced liver injury","volume":"15","author":"Kosinski","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/liv.14195","article-title":"Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug induced-liver injury from autoimmune hepatitis","volume":"39","author":"Weber","year":"2019","journal-title":"Liver Int."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1111\/liv.14224","article-title":"Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs","volume":"39","author":"Valgeirsson","year":"2019","journal-title":"Liver Int."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/apt.13159","article-title":"New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease","volume":"41","author":"Shelton","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jgh3.12054","article-title":"Differential characteristics in drug-induced autoimmune hepatitis","volume":"2","author":"Santos","year":"2018","journal-title":"JGH Open"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1111\/hepr.12532","article-title":"Natural history and outcomes in drug-induced autoimmune hepatitis","volume":"46","author":"Yeong","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00535-015-1131-7","article-title":"An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis","volume":"51","author":"Hisamochi","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Sakulsaengprapha, V., Wasuwanich, P., Naraparaju, G., Korotkaya, Y., Thawillarp, S., Oshima, K., Karwowski, C., Scheimann, A.O., and Karnsakul, W. (2023). Applicability of International Autoimmune Hepatitis Group (IAIGH) scoring system for autoimmune hepatitis in pediatrics. Biology, 12.","DOI":"10.3390\/biology12030479"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Petros, Z., Lee, M.-T.M., Takahashi, A., Zhang, Y., Yimer, G., Habtewold, A., Amogne, W., Aderaye, G., Schuppe-Koistinen, I., and Mushiroda, T. (2016). Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity. BMC Genom., 17.","DOI":"10.1186\/s12864-016-3078-3"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/j.jhep.2022.11.022","article-title":"Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort","volume":"78","author":"Daly","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/j.gastro.2016.12.016","article-title":"International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study","volume":"152","author":"Nicoletti","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt.1375","article-title":"Drug-induced liver injury due to Flucloxacillin: Relevance of multiple Human Leukocyte Antigen alleles","volume":"106","author":"Nicoletti","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_141","first-page":"117","article-title":"Failure to replicate a previously reported GWAS association between KCNJ1 gene and co-amoxiclav-induced liver injury","volume":"10","author":"Alshabeeb","year":"2021","journal-title":"Clin. Invest."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2022.09.010","article-title":"Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury","volume":"78","author":"Chalasani","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0016-5085(99)70404-X","article-title":"HLA association of amoxicillin-clavulanate\u2014Induced hepatitis","volume":"117","author":"Hautekeete","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/cts.13424","article-title":"Genetics of drug-induced liver injury: Current knowledge and future prospects","volume":"16","author":"Daly","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40264-022-01255-3","article-title":"Assessment of the frequency, phenotypes, and outcomes of acute liver injury associated with Amoxicillin\/Clavulanate in 1.4 million patients in the Veterans Health Administration","volume":"46","author":"Suzuki","year":"2023","journal-title":"Drug Saf."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Moreno-Torres, M., Quint\u00e1s, G., and Castell, J.V. (2022). The potential role of metabolomics in drug-induced liver injury (DILI) assessment. Metabolites, 12.","DOI":"10.3390\/metabo12060564"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Xie, Z., Zhang, L., Chen, E., Lu, J., Xiao, L., Liu, Q., Zhu, D., Zhang, F., Xu, X., and Li, L. (2021). Targeted metabolomics analysis of bile acids in patients with idiosyncratic drug-induced liver injury. Metabolites, 11.","DOI":"10.3390\/metabo11120852"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1007\/s00204-021-03114-z","article-title":"Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes","volume":"95","author":"Conde","year":"2021","journal-title":"Arch. Toxicol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"972518","DOI":"10.3389\/fmed.2022.972518","article-title":"Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis","volume":"9","author":"Fu","year":"2022","journal-title":"Front. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10855\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:03:41Z","timestamp":1760126621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":149,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241310855"],"URL":"https:\/\/doi.org\/10.3390\/ijms241310855","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}